Last reviewed · How we verify
COVID19 mRNA vaccine
COVID19 mRNA vaccine is a Biologic drug developed by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. It is currently in Phase 2 development for Prevention of COVID-19 disease caused by SARS-CoV-2 virus.
The COVID19 mRNA vaccine works by instructing cells to produce a piece of a viral protein, triggering an immune response to the virus.
The COVID19 mRNA vaccine works by instructing cells to produce a piece of a viral protein, triggering an immune response to the virus. Used for Prevention of COVID-19 disease caused by SARS-CoV-2 virus.
At a glance
| Generic name | COVID19 mRNA vaccine |
|---|---|
| Sponsor | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
This is achieved through the use of messenger RNA (mRNA) that encodes for a portion of the SARS-CoV-2 spike protein. Once the mRNA is taken up by cells, it is translated into the spike protein, which is then recognized by the immune system as foreign, triggering an immune response.
Approved indications
- Prevention of COVID-19 disease caused by SARS-CoV-2 virus
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations (PHASE4)
- Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction (PHASE4)
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
- Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (PHASE2, PHASE3)
- Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia. (PHASE3)
- COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose
- Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
- Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COVID19 mRNA vaccine CI brief — competitive landscape report
- COVID19 mRNA vaccine updates RSS · CI watch RSS
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico portfolio CI
Frequently asked questions about COVID19 mRNA vaccine
What is COVID19 mRNA vaccine?
How does COVID19 mRNA vaccine work?
What is COVID19 mRNA vaccine used for?
Who makes COVID19 mRNA vaccine?
What development phase is COVID19 mRNA vaccine in?
What are the side effects of COVID19 mRNA vaccine?
Related
- Manufacturer: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of COVID-19 disease caused by SARS-CoV-2 virus
- Compare: COVID19 mRNA vaccine vs similar drugs
- Pricing: COVID19 mRNA vaccine cost, discount & access